Al-Razi Pharma

What Al-Razi Pharma does

Al-Razi Pharma Industries is a Saudi national pharmaceutical manufacturer founded in 2011 and headquartered at the 2nd Industrial City in Dammam, Saudi Arabia, where it operates a 13,500 m² facility with 10,000 m² of covered production and storage space. The company is a wholly-owned subsidiary of Saeed Raddad Group (SRG), a diversified Saudi conglomerate founded in 1982 that employs over 20,000 people across the Kingdom. Al-Razi manufactures and distributes a portfolio of pharmaceutical products across six lines: small- and large-volume parenteral IV solutions (5ml to 500ml), hemodialysis solutions, oral solid dosage forms (tablets and capsules), eye drops, and Oral Dissolving Film (ODF) — the last being a novel drug delivery format the company positions as innovative.

The company's commercial model is enterprise field sales to healthcare providers (hospitals, clinics, and pharmacies) across Saudi Arabia and the GCC, executed through a direct, in-house distribution network rather than third-party wholesalers. All manufacturing is conducted under SFDA cGMP (license 34335), with ISO 9001:2015 and ISO 13485:2016 quality certifications; the company also maintains a dedicated pharmacovigilance function. There are no disclosed prices, named customers, revenue figures, or external institutional investors; ownership is entirely within the SRG family conglomerate. Marketing and brand-building efforts combine organic social channels (Facebook, Twitter, LinkedIn, Instagram), the corporate website, paid digital campaigns (signaled by recent digital marketing hiring), and participation in regional industry events such as Arab Health.

Name

Al-Razi Pharma

Legal name

Al-Razi Pharma Industries

Website

https://alrazi-pharma.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

101–250 employees

Short description

Al-Razi Pharma Industries is a Saudi national pharmaceutical manufacturer (founded 2011) producing IV solutions, hemodialysis solutions, oral solids, eye drops, and Oral Dissolving Film drugs, distributed across Saudi Arabia and the GCC.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA), Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Pharmaceutical manufacturing
• IV solutions production
• Oral solid dosage
• Hemodialysis solutions
• Oral dissolving film

Headquarters

HQ city

Dammam

HQ country

Saudi Arabia

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and distribution of pharmaceutical products including IV Solutions, Hemodialysis Solutions, Oral Solid Dosage forms (Tablets and Capsules), Eye Drops, and Oral Dissolving Film (ODF)

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Al-Razi Pharma Industries is a Saudi national pharmaceutical company that manufactures and distributes pharmaceutical products across Saudi Arabia and the GCC region. Its portfolio includes Small and Large Volume Parenteral IV Solutions, Hemodialysis Solutions, Oral Solid Dosage Forms (tablets and capsules), Eye Drops, and the innovative Oral Dissolving Film (ODF), all produced at its Dammam facility under SFDA cGMP standards.

Product overview

Al-Razi Pharma Industries is a Saudi national pharmaceutical company that operates as a single unified product portfolio focused on manufacturing and distribution of pharmaceutical products. The company produces a comprehensive range of life-saving and therapeutic pharmaceutical products including: Small Volume Parenteral and Large Volume Parenteral IV Solutions (5ml to 500ml), Hemodialysis Solutions, Oral Solid Dosage Forms (Tablets and Capsules), Eye Drops, and the innovative Oral Dissolving Film (ODF). All products are manufactured under SFDA cGMP standards and distributed across Saudi Arabia and the GCC region through the company's comprehensive distribution network.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• SRG (Saeed Raddad Group)coreOthersAl-Razi Pharma Industries is part of SRG (Saeed Raddad Group), founded in 1982, one of the oldest established independent companies in Saudi Arabia with over 20,000 employees operating throughout the Kingdom. SRG represents the parent company vision and contribution to serve Saudi and GCC communities through medical sector operations.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Tabuk Pharmaceuticals: One of the largest Saudi pharmaceutical manufacturers producing branded generics, injectables and specialty products. Comparable in being a Saudi-headquartered manufacturer selling across KSA and the wider MENA region with multi-dosage form capabilities.
• Saudi Arabian Pharmaceutical Industries (SAPI): Saudi national pharmaceutical manufacturer producing generic and branded medicines for the local market. Directly comparable as a fellow SFDA-licensed local manufacturer serving KSA healthcare providers with overlapping therapeutic coverage.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Leading Saudi pharmaceutical manufacturer producing generics across multiple dosage forms including tablets, capsules, syrups, injectables and ointments. Directly comparable as a homegrown Saudi cGMP-certified manufacturer serving KSA and export markets with overlapping product categories.
• AJA Pharmaceuticals: Saudi pharmaceutical manufacturer producing generic and specialty medicines across multiple dosage forms. Comparable as a fellow mid-sized Saudi cGMP manufacturer serving the same hospital and pharmacy channels.

Regional players

• EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest Egyptian pharmaceutical manufacturers producing generics across multiple dosage forms. Comparable as a MENA-based generics manufacturer serving overlapping GCC tender markets with similar product mix and regulatory profile.
• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer producing generics, injectables and consumer health products across the GCC. Comparable regional peer operating in the same geography with overlapping sterile injectable and OSD product portfolios.

Broad incumbents

• Hikma Pharmaceuticals: Jordan-headquartered multinational generic pharmaceutical manufacturer with significant MENA presence and strong sterile injectable franchise. Comparable as a broader regional incumbent with overlapping IV solutions and OSD product lines and deeper commercial reach.
• Cipla: Indian-headquartered multinational pharmaceutical company with a major respiratory, sterile and OSD generics portfolio and active Middle East distribution. Comparable as a broader incumbent exporting generics into KSA and GCC against local manufacturers like Al-Razi.
• Aurobindo Pharma: Indian multinational generic pharmaceutical manufacturer with a strong sterile injectables franchise and significant GCC presence. Comparable as a broader incumbent competing in the same IV solutions and OSD generic categories, especially in regional tenders.

Others

• Pharma Tech Industries: Regional pharmaceutical technology and manufacturing services provider. Relevant as an equipment/service ecosystem participant supporting pharmaceutical manufacturing in the GCC rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/alrazi-pharma-industry

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Al-Razi Pharma